Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
With
International Collaborative Cancer Group
Age
30–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
postmenopausal women with histologically or cytologically confirmed primary breast adenocarcinoma, receiving tamoxifen and have been treated with tamoxifen continuously for between 2 and 3 years and one month, and still free of disease
You may not be if
unresectable breast cancer
ER negative primary tumor
Clareo Health | Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer
